Form 4: Maze Therapeutics SVP Sells Shares After Option Exercise

Amy Bachrodt, SVP of Finance at Maze Therapeutics, executed pre-planned option exercises and subsequent sales of common stock, realizing significant gains.

Summary

• Amy Bachrodt, SVP of Finance at Maze Therapeutics, engaged in transactions involving the company's common stock.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 29, 2025.
• On January 2, 2026, Bachrodt exercised options to acquire 204 shares of common stock at $10.42 per share.
• Also on January 2, 2026, Bachrodt exercised options to acquire an additional 4,796 shares of common stock at $10.42 per share.
• Following these exercises, Bachrodt sold 2,405 shares at a weighted average price of $38.6995 per share, with prices ranging from $38.15 to $39.14.
• Additionally, 2,595 shares were sold at a weighted average price of $39.5689 per share, with prices ranging from $39.15 to $39.99.
• After all reported transactions, Bachrodt beneficially owns 12,965 shares of common stock directly.
• Bachrodt also holds remaining stock options to buy 2,377 and 2,983 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While an insider sold shares, it was a pre-planned transaction under a 10b5-1 plan, and the insider realized substantial profits, which could reflect positively on the company's stock performance leading up to the sale. The insider still retains a significant number of shares and options.

Positives

• The SVP of Finance realized significant profits from exercising options and selling shares at prices substantially higher than the exercise price ($10.42 vs. ~$39).
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned activity rather than a reactive sale.

Negatives

• An insider, the SVP of Finance, sold a portion of her common stock holdings.

Risks

• No specific risks related to the company's operations or financial health are detailed in this Form 4 filing. The inherent risk of stock ownership is present.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This filing is a standard insider transaction report and does not contain information suitable for comparison to global benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders may view the insider sale as a signal, though the 10b5-1 plan mitigates concerns about opportunistic selling.
• The SVP of Finance realized a significant personal gain, which is positive for the individual executive.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones beyond the execution of the existing 10b5-1 plan.

Key Dates

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Options, Executive Compensation, Rule 10b5-1, Amy Bachrodt